Thirty Years of Fighting for Animals in Laboratories
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Brain That Changes Itself
The Brain That Changes Itself Stories of Personal Triumph from the Frontiers of Brain Science NORMAN DOIDGE, M.D. For Eugene L. Goldberg, M.D., because you said you might like to read it Contents 1 A Woman Perpetually Falling . Rescued by the Man Who Discovered the Plasticity of Our Senses 2 Building Herself a Better Brain A Woman Labeled "Retarded" Discovers How to Heal Herself 3 Redesigning the Brain A Scientist Changes Brains to Sharpen Perception and Memory, Increase Speed of Thought, and Heal Learning Problems 4 Acquiring Tastes and Loves What Neuroplasticity Teaches Us About Sexual Attraction and Love 5 Midnight Resurrections Stroke Victims Learn to Move and Speak Again 6 Brain Lock Unlocked Using Plasticity to Stop Worries, OPsessions, Compulsions, and Bad Habits 7 Pain The Dark Side of Plasticity 8 Imagination How Thinking Makes It So 9 Turning Our Ghosts into Ancestors Psychoanalysis as a Neuroplastic Therapy 10 Rejuvenation The Discovery of the Neuronal Stem Cell and Lessons for Preserving Our Brains 11 More than the Sum of Her Parts A Woman Shows Us How Radically Plastic the Brain Can Be Appendix 1 The Culturally Modified Brain Appendix 2 Plasticity and the Idea of Progress Note to the Reader All the names of people who have undergone neuroplastic transformations are real, except in the few places indicated, and in the cases of children and their families. The Notes and References section at the end of the book includes comments on both the chapters and the appendices. Preface This book is about the revolutionary discovery that the human brain can change itself, as told through the stories of the scientists, doctors, and patients who have together brought about these astonishing transformations. -
Edward Taub ADDRESS: Department of Psychology 712 CPM University
CURRICULUM VITAE NAME: Edward Taub ADDRESS: Department of Psychology 712 CPM University of Alabama at Birmingham Birmingham, AL 35294-0018 Tel. No.: (205) 934-2471 Fax: (205) 975-6140 Email: [email protected] EDUCATION: B.A., Brooklyn College M.A., Columbia University Ph.D., New York University HONORS: 2012. The Estabrook Distinguished Research Scientist Award, Kessler Foundation. 2011, B.F. Skinner Lecture, Assoc. for Behavioral Analysis International (ABAI) President – Section J (Psychology), AAAS, 2009 CI therapy named by Soc. Neuroscience as 1 of 10 most exciting current lines of research in neuroscience (2005) Distinguished Scientific Award for the Applications of Psychology of the American Psychological Association (2004) CI therapy named by Soc. Neuroscience as 1 of top 10 Translational Neuroscience Accomplishments of 20th century (2003) Neal Miller Distinguished Research Lecture, American Psychological Association (2003) Leonard Diller Award, Division of Rehabilitation Psychology American Psychological Association (2001) Humboldt Fellow, Germany (2000 - 2005) William James Award, Amer. Psychol. Soc. (1997) Ireland Prize for Scholarly Distinction, Annual Award at Univ. Alabama at Birmingham (1997) Distinguished Scientist of 1996 Award, Association for Applied Psychophysiology and Biofeedback Scientist of Year Award – National Animal Interest Alliance (1993) Pioneering Research Contributions Award (1989), Association for Applied Psychophysiology and Biofeedback Distinguished Research Award, Biofeedback Society of America (1988) Guggenheim Fellow (1983-1985) President, Biofeedback Society of America (1978) Fellow, five societies Executive Board, four societies PROFESSIONAL HISTORY: Professor to University Professor, Department of Psychology, University of Alabama at Birmingham, 1986-present Guest Professor to Standing Guest Professor, University of Konstanz, 1995-2004 1 Guest Professor to Standing Guest Professor, University of Jena, 1996-2004 Visiting Professor - Universities of Tuebingen, Muenster, Hamburg, Humboldt Univ.1993-2002. -
(CCAC) Guide to the Care and Use of Experimental Animals Volume
Canadian Council on Animal Care Conseil canadien de protection des animaux Guide to the Care and Use of Experimental Animals Volume 1, 2nd Edition Sections of this document that have been revised are replaced by links to the relevant documents. The remaining sections are undergoing revision; however, they will continue to be used for CCAC assessments until revised guidelines are published. Editors Dr E.D. Olfert Dr B.M. Cross Mrs A.A. McWilliam Director Asssistant Director Information Officer Animal Resources Centre Animal Resources Centre Canadian Council on Animal Care University of Saskatchewan University of Saskatchewan 1000-151 Slater Street Saskatoon, Saskatchewan Saskatoon, Saskatchewan Ottawa, Ontario K1P 5H3 S7N 0W0 S7N 0W0 In keeping with the CCAC policy of revising statements and guidelines as needed, users of this Guide are encouraged to forward any comments to the Secretariat. Citing certain devices or manufacturers is not to be perceived as the endorsement of the Canadian Council on Animal Care (CCAC) of one particular product over another. Publication Date: 1993 Revision Date: April 2020 © Canadian Council on Animal Care, 1993 ISBN: 0-919087-18-3 Canadian Council on Animal Care 190 O’Connor St., Suite 800 Ottawa, Ontario, K2P 2R3 http://www.ccac.ca Table of Contents TABLE OF CONTENTS DEDICATION ...................................................................................................................1 PREFACE.........................................................................................................................2 -
Consideration of Alternatives to the Use of Live Animals for Research and Teaching
Division of Laboratory Animal Resources Consideration of Alternatives to the Use of Live Animals For Research and Teaching From the ETSU Animal Study Protocol form: The search for alternatives refers to the three Rs described in the book, The Principles of Humane Experimental Technique (1959) by Russell and Burch. The 3Rs are reduction in the number of animals used, refinement of techniques and procedures to reduce pain or distress, and replacement of animals with non-animal techniques or use of less-sentient species. Refinement: The use of analgesics and analgesia, the use of remote telemetry to increase the quality and quantity of data gathered, and humane endpoints for the animals are examples of refinements. Reduction: The use of shared control groups, preliminary screening in non-animal systems, innovative statistical packages or a consultation with a statistician are examples of reduction alternatives. Replacement: Alternatives such as in vitro, cell culture, tissue culture, models, simulations, etc. are examples of replacement. This is also where you might look for any non-mammalian animal models—fish or invertebrates, for example—that would still give you the data you need. The AWIC (Animal Welfare Information Center) recommends alternative searches be performed in 2 phases. Phase 1 considers reduction and refinement and the recommendation is NOT to use the word "alternative" unless the particular area of research happens to be an area in which there has been considerable work in developing alternatives (e.g. Toxicology and education). This phase should get after no unnecessary duplication, appropriate animal numbers, the best pain-relieving agents and other methods that may serve to minimize or limit pain and distress. -
Cruelty Free International
Cruelty Free International Sector: Household and Personal Care Region: Based in the United Kingdom, operates globally Cruelty Free International certifies brands producing cosmetics, personal care, household and cleaning products that do all they can to remove animal testing from their supply chains ('cruelty- free') and comply with the Leaping Bunny certification criteria. Cruelty Free International’s sustainability claim is the Leaping Bunny logo on products, which aims to allow shoppers to make more informed choices. Cruelty Free International and its partners have, so far, certified over 1000 brands around the world. Mindset Life Cycle Thinking: The claim focuses on the product manufacturing stage (i.e. the relevant phase where animal testing would occur). A supplier monitoring system must be implemented to monitor the claim, to ensure that the brand has not carried out, commissioned or been party to experiments on animals during the manufacturing of a product throughout its supply chain (including its raw materials and ingredients), whilst an independent and rigorous audit is conducted within the first 12 months of certification, and then every three years. Hotspots Analysis Approach: As a single-issue certification scheme, Cruelty Free International does not aim to assess all relevant impacts of the products it certifies and has therefore not undertaken a hotspots analysis. Cruelty Free International focuses on monitoring and enforcing high cruelty free standards throughout a brand’s manufacturing of a product. Mainstreaming Sustainability: Cruelty Free International encourages certified brands to apply the cruelty free logic to other products in their portfolio. Partnerships with ethical and cruelty free brands are also designed to support a brand's external sustainability and advocacy strategies and internal objectives. -
Animal Research Facilities Protection Act of 1989”
Historic, Archive Document Do not assume content reflects current scientific knowledge, policies, or practices. I kroosc r- i W^l ANIMAL RESEARCH FACILITY PROTECTION KF27 LfB w.d f? y .A33277 1990f - 9 /ggg Nyiloi JOINT HE GlfsjQ Pftpp BEFORE THE SUBCOMMITTEE ON DEPARTMENT OPERATIONS, RESEARCH, AND POREIGN AGRICULTURE AND THE SUBCOMMITTEE ON LIVESTOCK, DAIRY, AND POULTRY OF THE COMMITTEE ON AGRICULTURE HOUSE OF REPRESENTATIVES ONE HUNDRED FIRST CONGRESS SECOND SESSION FEBRUARY 28, 1990 Serial No. 101-52 Printed for the use of the Committee on Agriculture U.S. GOVERNMENT PRINTING OFFICE 17-873 WASHINGTON I 1991 For sale by the Superintendent of Documents, Congressional Sales Office REF U.S. Government Printing Office, Washington, DC 20402 United States Department of WAL' Agriculture GEOI CHAI GLEh % LEOh JERR DAN CHAI HAR( CHAI ROBI HARI JIM C TIMO RICH DAVI JIM J TIM t National Agricultural Library CLAU BEN : MIKE BILL Texas JILL L. LONG, Indiana GARY CONDIT, California ROY DYSON, Maryland H. MARTIN LANCASTER, North Carolina Professional Staff Dianne Powell, Staff Director Vernie Hubert, Legislative Director Daniel E. Brinza, Chief Counsel Charles Hilty, Minority Staff Director James A. Davis, Press Secretary Subcommittee on Department Operations, Research, and Foreign Agriculture GEORGE E. BROWN Jr., , California, Chairman CHARLES ROSE, North Carolina PAT ROBERTS, Kansas LEON E. PANETTA, California E. THOMAS COLEMAN, CHARLES W. STENHOLM, Missouri Texas SID MORRISON, Washington DAN GLICKMAN, Kansas FRED GRANDY, Iowa CHARLES HATCHER, Georgia JAMES T. WALSH, JIM OLIN, Virginia New York HAROLD L. VOLKMER, Missouri JIM JONTZ, Indiana Subcommittee on Livestock, Dairy, and Poultry CHARLES W. STENHOLM, Texas, Chairman JIM OLIN, Virginia STEVE GUNDERSON, BEN NIGHTHORSE Wisconsin CAMPBELL, Colorado LARRY J. -
The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models
International Journal of Clinical Medicine, 2014, 5, 966-1005 Published Online August 2014 in SciRes. http://www.scirp.org/journal/ijcm http://dx.doi.org/10.4236/ijcm.2014.516129 The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models Ray Greek Americans For Medical Advancement, Goleta, USA Email: [email protected] Received 11 June 2014; revised 10 July 2014; accepted 9 August 2014 Copyright © 2014 by author and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract The notion that animals could be used as predictive models in science has been influenced by rel- atively recent developments in the fields of complexity science, evolutionary and developmental biology, genetics, and evolutionary biology in general. Combined with empirical evidence, which has led scientists in drug development to acknowledge that a new, nonanimal model is needed, a theory—not a hypothesis—has been formed to explain why animals function well as models for humans at lower levels of organization but are unable to predict outcomes at higher levels of or- ganization. Trans-Species Modeling Theory (TSMT) places the empirical evidence in the context of a scientific theory and thus, from a scientific perspective, the issue of where animals can and can- not be used in science has arguably been settled. Yet, some in various areas of science or science- related fields continue to demand that more evidence be offered before the use of animal models in medical research and testing be abandoned on scientific grounds. -
Henry Spira Papers [Finding Aid]. Library of Congress. [PDF Rendered
Henry Spira Papers A Finding Aid to the Collection in the Library of Congress Manuscript Division, Library of Congress Washington, D.C. 2017 Contact information: http://hdl.loc.gov/loc.mss/mss.contact Additional search options available at: http://hdl.loc.gov/loc.mss/eadmss.ms017017 LC Online Catalog record: http://lccn.loc.gov/mm00084743 Prepared by Colleen Benoit, Karen Linn Femia, Nate Scheible with the assistance of Jake Bozza Collection Summary Title: Henry Spira Papers Span Dates: 1906-2002 Bulk Dates: (bulk 1974-1998) ID No.: MSS84743 Creator: Spira, Henry, 1927-1998 Extent: 120,000 items; 340 containers plus 6 oversize ; 140 linear feet ; 114 digital files (3.838 GB) Language: Collection material in English Location: Manuscript Division, Library of Congress, Washington, D.C. Summary: Animal welfare advocate and political activist. Correspondence, writings, notes, newspaper clippings, advertisements, printed matter, and photographs, primarily relating to Spira's work in the animal welfare movement after 1974. Selected Search Terms The following terms have been used to index the description of this collection in the Library's online catalog. They are grouped by name of person or organization, by subject or location, and by occupation and listed alphabetically therein. People Douglas, William Henry James. Fitzgerald, Pegeen. Gitano, Henry, 1927-1998. Grandin, Temple. Kupferberg, Tuli. Rack, Leonard. Rowan, Andrew N. Singer, Peter, 1946- Singer, Peter, 1946- Ethics into action : Henry Spira and the animal rights movement. 1998. Spira, Henry, 1927-1998--Political and social views. Spira, Henry, 1927-1998. Trotsky, Leon, 1879-1940. Trull, Frankie. Trutt, Fran. Weiss, Myra Tanner. Organizations American Museum of Natural History. -
Innovative Delivery of Sirna to Solid Tumors by Super Carbonate Apatite
RESEARCH ARTICLE Innovative Delivery of siRNA to Solid Tumors by Super Carbonate Apatite Xin Wu1,2, Hirofumi Yamamoto1*, Hiroyuki Nakanishi3, Yuki Yamamoto3, Akira Inoue1, Mitsuyoshi Tei1, Hajime Hirose1, Mamoru Uemura1, Junichi Nishimura1, Taishi Hata1, Ichiro Takemasa1, Tsunekazu Mizushima1, Sharif Hossain4,5, Toshihiro Akaike4,5, Nariaki Matsuura6, Yuichiro Doki1, Masaki Mori1 1 Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan, 2 Research Fellow of Japan Society for the Promotion of Science, Tokyo, Japan, 3 Nakanishi Gastroenterological Research Institute, Sakai, Japan, 4 Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan, 5 Biomaterials Center for Regenerative Medical Engineering, Foundation for Advancement of International Science, Tsukuba, Japan, 6 Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan * [email protected] Abstract RNA interference (RNAi) technology is currently being tested in clinical trials for a limited OPEN ACCESS number of diseases. However, systemic delivery of small interfering RNA (siRNA) to solid tumors has not yet been achieved in clinics. Here, we introduce an in vivo pH-sensitive de- Citation: Wu X, Yamamoto H, Nakanishi H, livery system for siRNA using super carbonate apatite (sCA) nanoparticles, which is the Yamamoto Y, Inoue A, Tei M, et al. (2015) Innovative Delivery of siRNA to Solid Tumors by Super smallest class of nanocarrier. These carriers consist simply of inorganic ions and accumu- Carbonate Apatite. PLoS ONE 10(3): e0116022. late specifically in tumors, yet they cause no serious adverse events in mice and monkeys. doi:10.1371/journal.pone.0116022 Intravenously administered sCA-siRNA abundantly accumulated in the cytoplasm of tumor Academic Editor: Sung Wan Kim, University of cells at 4 h, indicating quick achievement of endosomal escape. -
The Animal Welfare Act at Fifty: Problems and Possibilities in Animal Testing Regulation
University of the Pacific Scholarly Commons McGeorge School of Law Scholarly Articles McGeorge School of Law Faculty Scholarship 2016 The Animal Welfare Act at Fifty: Problems and Possibilities in Animal Testing Regulation Courtney G. Lee Pacifc McGeorge School of Law Follow this and additional works at: https://scholarlycommons.pacific.edu/facultyarticles Part of the Animal Law Commons Recommended Citation Courtney G. Lee, The Animal Welfare Act at Fifty: Problems and Possibilities in Animal Testing Regulation, 95 Neb. L. Rev. 194 (2016). This Article is brought to you for free and open access by the McGeorge School of Law Faculty Scholarship at Scholarly Commons. It has been accepted for inclusion in McGeorge School of Law Scholarly Articles by an authorized administrator of Scholarly Commons. For more information, please contact [email protected]. Courtney G. Lee* The Animal Welfare Act at Fifty: Problems and Possibilities in Animal Testing Regulation TABLE OF CONTENTS I. Introduction .......................................... 195 II. Background of the Animal Welfare Act ................ 196 A. Enactment and Evolution.......................... 196 B. Early Amendments ................................ 197 C. Improved Standards for Laboratory Animals Act of 1985 .............................................. 198 D. Institutional Animal Care and Use Committees .... 201 E. IACUC Effectiveness .............................. 203 III. Coverage of the AWA .................................. 205 A. What Is an “Animal” under the AWA? ............. -
The Case Against Animal Experiments
The Case Against Animal Experiments Animal experiments are both unethical and unscientific. Animals in laboratories endure appalling suffering, such as being deliberately poisoned, brain-damaged and subjected to inescapable electric shocks. The pain and misery inflicted on the victims is enough, on its own, to make vivisection worthy of public condemnation. But animal “ “ experiments are also bad science, since the results they produce cannot be reliably translated to humans. They therefore offer little hope of advancing medical progress. The Case Against Animal Experiments outlines the suffering of animals used in research, before providing a clear, non-technical description of the scientific problems S E with vivisection. L I www.animalaid.org.uk C I N I M O D © How animals are used Contents Each year around four million How animals are used .......................... 1 animals are experimented on inside British laboratories. The suffering of animals in Dogs, cats, horses, monkeys, laboratories ........................................ 2 rats, rabbits and other animals Cruel experiments .................................... 2 are used, as well as hundreds A failing inspection regime ........................ 3 of thousands of genetically Secrecy and misinformation ...................... 4 modified mice. The most The GM mouse myth ................................ 4 common types of experiment The scientific case against either attempt to test how animal experiments .............................. 5 safe a substance is (toxicity Summary ............................................... -
The Use of Animals for Research in the Pharmaceutical Industry
Chapter 8 The use of animals for research in the pharmaceutical industry The ethics of research involving animals The use of animals for research in the CHAPTER 8 pharmaceutical industry Introduction THE USE OF ANIMALS FOR RESEARCH IN PHARMACEUTICAL INDUSTRY 8.1 The pharmaceutical industry conducts or supports approximately one third of the animal research that is undertaken in the UK. Some of this is basic research that seeks to examine normal biological processes and the nature of disease (see also Chapters 5 and 6). However, most has more specific, applied objectives and concerns the development of new medicines or vaccines, improved diagnosis or better methods of toxicity testing. Since the process of producing medicines has changed significantly over time, we begin with a brief overview of developments from the late 19th century to the present. We then describe the way medicines are currently produced in terms of eight stages. These are: discovery and selection of compounds that could be effective medicines (stages 1 and 2), characterisation of promising candidate medicines (stages 3 and 4), selecting candidate medicines and ensuring their safety (stage 5), clinical studies on humans (stages 6 to 8), and also research carried out to support the medicine once it has been marketed. For each stage we describe the way in which animals are used in the process, and give some examples of specific experiments. As in the case of research described in the previous chapters, welfare implications for the animals involved in pharmaceutical research are as diverse as the types of research and must be considered on a case by case basis.